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Abstract
Background: Combination lithium, a mood stabilizer, and risperidone, an atypical antipsychotic drug, is widely
used for treatment of psychotic disorders. Rare reports concern severe adverse drug reaction in multiple organic
systems with their combined use. We report two episodes of neurotoxicity and nephrotoxicity in a patient
following the combined use of lithium and risperidone.
Case presentation: A 55-year-old male had a diagnosis of schizoaffective disorder at the age of 51. He was initially
treated with a combination of lithium and olanzapine 5 to 15 mg/day for 2 years. He was admitted to psychiatric
ward at the age of 53 due to manic episode with psychotic feature. Because of poor blood sugar control, we
switched olanzapine 20 mg/day to risperidone 4.5 mg/day with combination of lithium 900mg/day. The patient
presented neurotoxicity, neuroleptic-malignant-syndrome like symptoms, and nephrotoxicity, elevation of blood
creatinine and decreased urine output few days later. These signs were fully recovered within 2 days after we
discontinued all medications and gave normal saline hydration. Then we re-administered decreased dosage of
lithium 600 mg/day and risperidone 3 mg/day, and the similar episode occurred again 3 days later. All drugs were
discontinued again, then his delirium resolved and abnormal data returned to normal 1 day later. Finally, the
patient was treated with risperidone 2 mg/day as monotherapy, and no episode of neurotoxicity and
nephrotoxicity appeared in the following 2 years.
Conclusions: The case exemplifies neurotoxicity and nephrotoxicity after combined use of lithium and risperidone.
These adverse effects resolved soon after discontinuing these medications and adequate hydration. Clinicians
should be cautious about neurological and renal adverse effects.
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Background
Lithium is a mood stabilizer for treatment of bipolar
disorders [1]. Risperidone, an atypical antipsychotic drug
with both dopamine D2 antagonistic and serotonin 5-
HT2A antagonistic properties, is widely used for treat-
ment of psychotic disorders. Combination of lithium
and risperidone is commonly used for bipolar disorder
or schizoaffective disorder [2]. There are rare reports
concerning severe adverse drug reaction, neurotoxicity,
with their combined use (Table 1) [3–9]. We report a
patient who presented not only neurotoxicity but also
nephrotoxicity following the combined use of lithium
and risperidone.
Case presentation
A 55-year-old male had a diagnosis of schizoaffective
disorder at the age of 51. He was initially diagnosed with
bipolar I disorder at the age of 30, and mainly treated
with a combination of lithium and valproic acid from
age 30 to 51. At the age of 51, he was observed to have a
manic episode concurrent with persecutory delusions
and auditory hallucination. These psychotic symptoms
persisted for more than 3 weeks after his manic symp-
toms had subsided. Later, a combination of lithium and
olanzapine 5 to 15 mg/day were given as the main
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treatment. In addition, he had history of type 2 diabetes
mellitus and hyperlipidemia for more than 10 years. He
did not have any substance use or neurological disorder
before. This time, after poor drug adherence for 4
months, he was admitted to our ward at the age of 53,
due to symptoms including elevated mood, increased
goal-directed activity, talkativeness, decreased need for
sleep, and grandiose delusion lasting for 1 week.
Lithium 600 mg/day and olanzapine 10 mg/day were
initially prescribed, and the dosages were titrated to 900
mg/day and 20 mg/day, respectively, over 1 week. His
lithium serum level was reported to be 0.60 mEq/L (day
4) and 0.58 mEq/L (day 14). Because of poor blood sugar
control, intramuscular injection of risperidone 25 mg
was prescribed for switching antipsychotic agent on day
15. Olanzapine was discontinued and risperidone 4.5
mg/day was started on days 22 to 24. However, on day
27, the patient presented slurred speech, muscle rigidity,
delirium (confused consciousness, inattention, and dis-
orientation), and decreased urine output. At the same
time, he did not present fever, focal neurological signs,
or gastrointestinal symptoms. Laboratory data showed:
blood urea nitrogen (BUN; 24 mg/dL), creatinine (1.33
mg/dL), serum lithium (1.42 mEq/L) on day 28, and cre-
atine kinase (975 U/L) on day 29, compared with BUN
(8 mg/dL) and creatinine (0.8 mg/dL) on admission. All
medications were discontinued and he was treated with
normal saline hydration. The delirium and abnormal
laboratory data were fully recovered within 2 days, as
follows: BUN (12 mg/dL), creatinine (0.82 mg/dL), and
serum lithium (0.82 mEq/L). Lithium 600 mg/day and
risperidone 3 mg/day were re-administered on day 32.
But symptoms of delirium and elevated BUN (29 mg/
dL), creatinine (1.36 mg/dL), serum lithium (1.54 mEq/
L), and creatine kinase (90 U/L) were noted on day 35.
All drugs were discontinued again and fluid hydration
was given. One day later, the delirium resolved and
abnormal data returned to normal: BUN (16 mg/dL),
creatinine (0.88 mg/dL), and serum lithium (1.06 mEq/
L). Finally, risperidone 2 mg/day monotherapy was given
on day 38. The patient was discharged in a stable condi-
tion on day 42. He was kept regular treatment with ris-
peridone 2 to 3 mg/day, and no episode of neurotoxicity
and nephrotoxicity appeared in the following 2 years.
Conclusions
Our patient had 2 episodes of neurotoxicity and nephro-
toxicity during this hospitalization. He presented delir-
ium, acute kidney injury (AKI) with increased level of
serum creatinine [10], and lithium intoxication, which
had developed soon after combined administration of
lithium and risperidone, and subsided after discontinu-
ing these medications. There were no other obvious
medical causes that could better account for the devel-
opment of above symptoms in this patient. The switch-
ing of antipsychotics was suitable for our patient with
history of type 2 diabetes mellitus and hyperlipidemia
[11]. His clinical features were considered to be side
effects of lithium-risperidone interaction. The rating on
the Naranjo Adverse Drug Reaction Probability Scale
was 10, considered a “definite” adverse effect [12].
We searched PubMed from inception to June 2016 for
literature review of neurotoxicity and nephrotoxicity due
to combined use of lithium and risperidone. Google
Scholar and pharmacovigilance databases of UK, Dutch,
Australian, and Canadian were also searched for add-
itional relevant articles. The search terms were: “lithium”
and “risperidone” and (neuroto* or nms or neuroleptic
malignant syndrome or delirium) as Search 1; lithium
and risperidone and (nephroto* or renal failure or kidney
injury) as Search 2. Articles without the direct concomi-
tant use of lithium and risperidone or with toxicity
highly related to other physical problem or obscure sup-
port were excluded. The Search 1 and 2 finally yielded 7
Table 1 Seven previous reports and 2 episodes of neurotoxicity and nephrotoxicity in our patient caused by combined use of
lithium and risperidone
R.N. Age Sex Diagnosis Risperidone dose (mg) Lithium dose (mg) Time to onseta Clinical presentation Laboratory values and Image
[3] 69 F BD 6 450 3 weeks Delirium Cr: NA; Li: 1.36
[4] 30 M BD NA 900 1 week NMS Cr: 1.6; Li: 0.6; CPK: 1428
[5] 46 M NA 3 900 2 years NMS, DKA BUN: 66
[6] 54 F BD 3 1500 2 months NMS Cr: NA; Li: 0.7; CPK: 791
[7] 60 F SD 6 NA 3 weeks Delirium EEG: Abnormal; CK: 953
[8] 75 M BD 2 900 4 days Lethargy EEG: Abnormal; Cr: NA; Li: 1.47
[9] 60 F SD 6 NA 6 days NMS EEG: Abnormal; CPK: 953
Ib 56 M SD 4.5c 900 12 days Delirium BUN/Cr: 24/1.33; Li: 1.42; CK: 975
IIb 3 600 3 days Delirium BUN/Cr: 29/1.36; Li: 1.54; CK: 90
aTime is calculated from beginning the combination of lithium and risperidone to the occurrence of adverse events
bI and II are serial numbers of the 2 episodes of our patient during hospitalization
cIM Risperidone 25 mg/vial was prescribed 7 days before oral risperidone
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articles (twenty results from PubMed, then 14 articles
were excluded and 1 report were included from Google
Scholar) and showed in Table 1 [3–9]. These cases
showed the mean age of 56.3 years, and no gender
difference (4 females). The doses of lithium and risperi-
done ranged from 450 to 1500 mg/day and 2 to 6 mg/
day, respectively, which are within normal therapeutic
range. Side effects were noted within 3 weeks (5 of 7
cases) after the initial combination of lithium and risper-
idone, and varied from 4 days to 2 years. All cases devel-
oped neurotoxicity with symptoms of lethargy, delirium,
and even neuroleptic malignant syndrome (NMS) (4 of 7
cases). NMS is characterized by delirium, muscular ri-
gidity, fever, and autonomic nervous system dysregula-
tion with typically high levels of creatine phosphokinase
but not necessary in elevation of creatinine [13, 14].
Furthermore, our report specially showed the change of
renal function in detail compared to previous reports.
There are two hypotheses of neurotoxicity from drug-
drug interaction between lithium and risperidone. One
is pure lithium intoxication-induced neurotoxicity with-
out a relationship with risperidone [8]. The other one is
that both lithium and risperidone increase the dopamine
receptor blockade. Lithium inhibits pre-synaptic dopa-
mine release, and risperidone blocks dopamine receptors
[9]. As for nephrotoxicity, there are inconsistent results.
One study including 13 patients indicates that switching
a combination of lithium plus a conventional anti-
psychotic to a combination of lithium plus risperidone
within 9 days is generally well tolerated and no statisti-
cally significant differences in the pharmacokinetics of
serum lithium [15]. The other studies support lithium
and risperidone may each induce it. Lithium may impair
tubular function and next result in several renal compli-
cations, including AKI [16, 17]. Risperidone was also
described as increasing the risk of AKI in a population-
based cohort study [18]. Our case is an indicator to
prove the nephrotoxicity by the concomitant use of these
pharmaceuticals. He did not have a history of AKI while
being treated with lithium or risperidone alone. We
assume his AKI have a “2-pronged” effect of nephrotox-
icity, which causes functional impairment of nephrons.
Based on the literature review and our report, close
observation of neurological signs for at least 3 weeks is
necessary when lithium and risperidone are used at the
same time. Once neurotoxicity occurs, further monitor-
ing of renal function for nephrotoxicity survey is also
required. Discontinuance of these agents will lead to
remission of the aforementioned adverse effects.
Abbreviation
BD: Bipolar disorder; BUN: Blood urea nitrogen; CPK: Creatine phosphokinase;
Cr: Creatinine; DKA: Diabetic ketoacidosis; EEG: Electroencephalography;
Li: Lithium; NA: Not available; NMS: Neuroleptic malignant syndrome;
R.N.: Reference number; SD: Schizoaffective disorder
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